乳房外Paget病发病机制研究进展

doi:10.35541/cjd.20220588

中华皮肤科杂志 ›› 2023, e20220588.doi: 10.35541/cjd.20220588

乳房外Paget病发病机制研究进展

丁玫琳李弘扬张韡曾学思

中国医学科学院北京协和医学院皮肤病医院病理科，南京 210042

收稿日期:2022-08-24 修回日期:2023-04-05 发布日期:2023-07-12
通讯作者: 张韡 E-mail:ifmtjoel@163.com
基金资助:
中国医学科学院临床与转化医学研究基金（2020-I2M-C&T-B-091）；西藏自治区自然科学基金［XZ2021ZR-ZY12（Z）］

Pathogenesis of extramammary Paget′s disease

Ding Meilin, Li Hongyang, Zhang Wei, Zeng Xuesi

Department of Pathology, Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Received:2022-08-24 Revised:2023-04-05 Published:2023-07-12
Contact: Zhang Wei E-mail:ifmtjoel@163.com
Supported by:
CAMS Innovation Fund for Medical Sciences （2020-I2M-C&T-B-091）; Natural Science Foundation of Tibet Autonomous Region ［XZ2021ZR-ZY12（Z）］

摘要/Abstract

摘要： 【摘要】乳房外Paget病（EMPD）通常发生在顶泌汗腺分化区域，其中Paget细胞散在分布于表皮中下部，单个或成簇，并向全层播散。EMPD的发病机制尚不清楚，细胞起源仍存在争论。本文从组织发生、驱动基因、信号转导通路及免疫环境四个方面探讨EMPD的发病机制，重点关注相关研究进展。

关键词: 佩吉特病, 乳腺外, 发病机制, 组织发生, 驱动基因, 信号转导通路, 免疫环境

Abstract: 【Abstract】 Extramammary Paget′s disease （EMPD） usually occurs in the apocrine gland-bearing areas, in which Paget cells are scattered in the middle and lower epidermis, arranged singly or in clusters, and spread to all skin layers. The pathogenesis of EMPD is still unclear, and the origin of Paget cells remains controversial. This review discusses the pathogenesis of EMPD from 4 aspects, i.e., histogenesis, driver genes, signal transduction pathways and immune environment, and focuses on relevant research progress.

Key words: Paget disease, extramammary, Pathogenesis, Histogenesis, Driver genes, Signal transduction pathways, Immune environment

丁玫琳李弘扬张韡曾学思. 乳房外Paget病发病机制研究进展[J]. 中华皮肤科杂志, 2023,e20220588. doi:10.35541/cjd.20220588

Ding Meilin, Li Hongyang, Zhang Wei, Zeng Xuesi. Pathogenesis of extramammary Paget′s disease[J]. Chinese Journal of Dermatology,2023,e20220588. doi:10.35541/cjd.20220588

参考文献 49

［1］	Siesling S, Elferink MA, van Dijck JA, et al. Epidemiology and treatment of extramammary Paget disease in the Netherlands［J］. Eur J Surg Oncol, 2007,33（8）:951⁃955. doi: 10.1016/j.ejso.2006. 11.028.
［2］	Wigley C, Zargaran D, Nikkhah D, et al. Ectopic extramammary Paget′s disease of the abdominal wall with abdominoplasty reconstruction［J］. BMJ Case Rep, 2022,15（3）:e243322. doi: 10.1136/bcr⁃2021⁃243322.
［3］	Tan L, Huang J, Zhang Y, et al. Evaluation of in vivo reflectance confocal microscopy in the diagnosis of extramammary Paget′s disease［J］. Microsc Res Tech, 2022,85（1）:283⁃289. doi: 10. 1002/jemt.23903.
［4］	Scarbrough CA, Vrable A, Carr DR. Definition, association with malignancy, biologic behavior, and treatment of ectopic extramammary Paget′s disease: a review of the literature［J］. J Clin Aesthet Dermatol, 2019,12（8）:40⁃44.
［5］	Fusumae T, Fukuda K, Hirai I, et al. Management and outcomes of hydronephrosis in patients with metastatic extramammary Paget′s disease: a retrospective analysis［J］. J Dermatol, 2022,49（8）:787⁃791. doi: 10.1111/1346⁃8138.16407.
［6］	Shah VI, Bergin L, Rowlands GL, et al. Unusual manifestations of vulval Paget disease［J］. Int J Gynecol Pathol, 2022,41（5）:476⁃483. doi: 10.1097/PGP.0000000000000824.
［7］	Simonds RM, Segal RJ, Sharma A. Extramammary Paget′s disease: a review of the literature［J］. Int J Dermatol, 2019,58（8）:871⁃879. doi: 10.1111/ijd.14328.
［8］	张韡, 曾学思, 孙建方. 乳房外 Paget 病的病理学研究进展［J］. 中华皮肤科杂志, 2015,48（12）:897⁃898. doi: 10.3760/cma.j.issn.0412⁃4030.2015.12.023.
［9］	Karpathiou G, Mobarki M, Papoudou⁃Bai A, et al. Autophagic factors in Paget disease［J］. Pathol Res Pract, 2022,236:154001. doi: 10.1016/j.prp.2022.154001.
［10］	Chang YW, Ma H, Liao WC. Survival analysis of extramammary Paget′s disease （EMPD） in a tertiary hospital in Taiwan［J］. World J Surg Oncol, 2021,19（1）:110. doi: 10.1186/s12957⁃021⁃02228⁃z.
［11］	Lam C, Funaro D. Extramammary Paget′s disease: summary of current knowledge［J］. Dermatol Clin, 2010,28（4）:807⁃826. doi: 10.1016/j.det.2010.08.002.
［12］	Marucci G, Betts CM, Golouh R, et al. Toker cells are probably precursors of Paget cell carcinoma: a morphological and ultrastructural description［J］. Virchows Arch, 2002,441（2）:117⁃123. doi: 10.1007/s00428⁃001⁃0581⁃x.
［13］	Smith AA. Pre⁃Paget cells express a Paget cell marker before losing a keratinocyte marker［J］. Intractable Rare Dis Res, 2021,10（1）:58⁃59. doi: 10.5582/irdr.2020.03086.
［14］	Belousova IE, Kazakov DV, Michal M, et al. Vulvar toker cells: the long⁃awaited missing link: a proposal for an origin⁃based histogenetic classification of extramammary paget disease［J］. Am J Dermatopathol, 2006,28（1）:84⁃86. doi: 10.1097/01.dad. 0000194052.65695.f1.
［15］	Hutchings D, Windon A, Assarzadegan N, et al. Perianal Paget′s disease as spread from non⁃invasive colorectal adenomas［J］. Histopathology, 2021,78（2）:276⁃280. doi: 10.1111/his.14218.
［16］	Nowak MA, Guerriere⁃Kovach P, Pathan A, et al. Perianal Paget′s disease: distinguishing primary and secondary lesions using immunohistochemical studies including gross cystic disease fluid protein⁃15 and cytokeratin 20 expression［J］. Arch Pathol Lab Med, 1998,122（12）:1077⁃1081.
［17］	Liao X, Liu X, Fan X, et al. Perianal Paget′s disease: a clinicopathological and immunohistochemical study of 13 cases［J］. Diagn Pathol, 2020,15（1）:29. doi: 10.1186/s13000⁃020⁃00952⁃w.
［18］	Tekin B, Kundert P, Yang HH, et al. CDX2 expression in primary skin tumors⁃case series and review of the literature［J］. Hum Pathol, 2022,129:1⁃10. doi: 10.1016/j.humpath.2022.07. 013.
［19］	Zhang G, Zhou S, Zhong W, et al. Whole⁃exome sequencing reveals frequent mutations in chromatin remodeling genes in mammary and extramammary Paget′s diseases［J］. J Invest Dermatol, 2019,139（4）:789⁃795. doi: 10.1016/j.jid.2018.08.030.
［20］	Kiniwa Y, Yasuda J, Saito S, et al. Identification of genetic alterations in extramammary Paget disease using whole exome analysis［J］. J Dermatol Sci, 2019,94（1）:229⁃235. doi: 10.1016/j.jdermsci.2019.03.006.
［21］	Kang Z, Xu F, Zhang QA, et al. Oncogenic mutations in extramammary Paget′s disease and their clinical relevance［J］. Int J Cancer, 2013,132（4）:824⁃831. doi: 10.1002/ijc.27738.
［22］	Kusaba Y, Kajihara I, Myangat TM, et al. Intertumor and intratumor heterogeneity of PIK3CA mutations in extramammary Paget′s disease［J］. J Dermatol, 2022,49（5）:508⁃514. doi: 10. 1111/1346⁃8138.16343.
［23］	Ishida Y, Kakiuchi N, Yoshida K, et al. Unbiased detection of driver mutations in extramammary Paget disease［J］. Clin Cancer Res, 2021,27（6）:1756⁃1765. doi: 10.1158/1078⁃0432.CCR⁃20⁃3205.
［24］	Takeichi T, Okuno Y, Matsumoto T, et al. Frequent FOXA1⁃activating mutations in extramammary Paget′s disease［J］. Cancers （Basel）, 2020,12（4）:820. doi: 10.3390/cancers12040820.
［25］	Zhang Y, Zhang D, Li Q, et al. Nucleation of DNA repair factors by FOXA1 links DNA demethylation to transcriptional pioneering［J］. Nat Genet, 2016,48（9）:1003⁃1013. doi: 10.1038/ng.3635.
［26］	Sawamura S, Mijiddorj Myangat T, Kajihara I, et al. Genomic landscape of circulating tumour DNA in metastatic extramammary Paget′s disease［J］. Exp Dermatol, 2022,31（3）:341⁃348. doi: 10.1111/exd.14476.
［27］	Tanaka R, Sasajima Y, Tsuda H, et al. Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease［J］. Clin Exp Metastasis, 2016,33（7）:687⁃697. doi: 10.1007/s10585⁃016⁃9804⁃z.
［28］	Maeda T, Kitamura S, Nishihara H, et al. Extramammary Paget′s disease patient⁃derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2⁃targeted therapies［J］. Oncogene, 2020,39（36）:5867⁃5875. doi: 10.1038/s41388⁃020⁃01404⁃x.
［29］	Bartoletti M, Mazzeo R, De Scordilli M, et al. Human epidermal growth factor receptor⁃2 （HER2） is a potential therapeutic target in extramammary Paget′s disease of the vulva［J］. Int J Gynecol Cancer, 2020,30（11）:1672⁃1677. doi: 10.1136/ijgc⁃2020⁃001771.
［30］	Tokuchi K, Maeda T, Kitamura S, et al. HER2⁃targeted antibody⁃drug conjugates display potent antitumor activities in preclinical extramammary Paget′s disease models: in vivo and immuno⁃histochemical analyses［J］. Cancers （Basel）, 2022,14（14）:3519. doi: 10.3390/cancers14143519.
［31］	Liegl B, Horn LC, Moinfar F. Androgen receptors are frequently expressed in mammary and extramammary Paget′s disease［J］. Mod Pathol, 2005,18（10）:1283⁃1288. doi: 10.1038/modpathol. 3800437.
［32］	Azmahani A, Nakamura Y, Ozawa Y, et al. Androgen receptor, androgen⁃producing enzymes and their transcription factors in extramammary Paget disease［J］. Hum Pathol, 2015,46（11）:1662⁃1669. doi: 10.1016/j.humpath.2015.07.007.
［33］	Angelico G, Santoro A, Inzani F, et al. Hormonal environment and HER2 status in extra⁃mammary paget′s disease （eMPD）: a systematic literature review and meta⁃analysis with clinical considerations［J］. Diagnostics （Basel）, 2020,10（12）:1040. doi: 10.3390/diagnostics10121040.
［34］	Chang K, Li GX, Kong YY, et al. Chemokine receptors CXCR4 and CXCR7 are associated with tumor aggressiveness and prognosis in extramammary paget disease［J］. J Cancer, 2017,8（13）:2471⁃2477. doi: 10.7150/jca.19127.
［35］	Urata K, Kajihara I, Myangat TM, et al. Overexpression of cyclin⁃dependent kinase 4 protein in extramammary Paget′s disease［J］. J Dermatol, 2019,46（5）:444⁃448. doi: 10.1111/1346⁃8138. 14858.
［36］	Kitamura S, Yanagi T, Maeda T, et al. Cyclin⁃dependent kinase 4/6 inhibitors suppress tumor growth in extramammary Paget′s disease［J］. Cancer Sci, 2022,113（2）:802⁃807. doi: 10.1111/cas.15234.
［37］	Urano⁃Takaoka M, Sumida H, Miyagawa T, et al. Serum cytokeratin 18 as a metastatic and therapeutic marker for extramammary Paget′s disease［J］. Acta Derm Venereol, 2022,102:adv00636. doi: 10.2340/actadv.v101.866.
［38］	Chen S, Nakahara T, Uchi H, et al. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget′s disease［J］. Br J Dermatol, 2009,161（2）:357⁃363. doi: 10.1111/j.1365⁃2133.2009.09179.x.
［39］	van der Linden M, van Esch E, Bulten J, et al. The immune cell infiltrate in the microenvironment of vulvar Paget disease［J］. Gynecol Oncol, 2018,151（3）:453⁃459. doi: 10.1016/j.ygyno.2018. 09.026.
［40］	Press JZ, Allison KH, Garcia R, et al. FOXP3+ regulatory T⁃cells are abundant in vulvar Paget′s disease and are associated with recurrence［J］. Gynecol Oncol, 2011,120（2）:296⁃299. doi: 10.1016/j.ygyno.2010.10.019.
［41］	González⁃Suárez E, Sanz⁃Moreno A. RANK as a therapeutic target in cancer［J］. FEBS J, 2016,283（11）:2018⁃2033. doi: 10.1111/febs.13645.
［42］	Kambayashi Y, Fujimura T, Furudate S, et al. The possible interaction between receptor activator of nuclear factor kappa⁃B ligand expressed by extramammary Paget cells and its ligand on dermal macrophages［J］. J Invest Dermatol, 2015,135（10）:2547⁃2550. doi: 10.1038/jid.2015.199.
［43］	Fujimura T, Kambayashi Y, Furudate S, et al. Receptor activator of NF⁃κB ligand promotes the production of CCL17 from RANK+ M2 macrophages［J］. J Invest Dermatol, 2015,135（11）:2884⁃2887. doi: 10.1038/jid.2015.209.
［44］	Karpathiou G, Chauleur C, Hathroubi S, et al. Expression of CD3, PD⁃L1 and CTLA⁃4 in mammary and extra⁃mammary Paget disease［J］. Cancer Immunol Immunother, 2018,67（8）:1297⁃1303. doi: 10.1007/s00262⁃018⁃2189⁃x.
［45］	Maeda T, Uehara J, Toyoshima R, et al. Neutrophil⁃to⁃lymphocyte ratio is a potential prognostic biomarker for extramammary Paget disease: a retrospective study［J］. J Dermatol, 2022,49（11）:1188⁃1192. doi: 10.1111/1346⁃8138.16533.
［46］	Kawaguchi A, Akiba J, Kondo R, et al. Programmed death⁃ligand 1 and programmed death⁃ligand 2 expression can affect prognosis in extramammary Paget′s disease［J］. Anticancer Res, 2021,41（1）:219⁃226. doi: 10.21873/anticanres.14768.
［47］	Chuang KC, Chang CR, Chang SH, et al. Imiquimod⁃induced ROS production disrupts the balance of mitochondrial dynamics and increases mitophagy in skin cancer cells［J］. J Dermatol Sci, 2020,98（3）:152⁃162. doi: 10.1016/j.jdermsci.2020.03.009.
［48］	Borella F, Preti M, Vieira⁃Baptista P, et al. Vulvar Paget′s disease: outcomes of 51 patients treated with imiquimod cream［J］. Maturitas, 2022,163:23⁃27. doi: 10.1016/j.maturitas.2022. 05.010.
［49］	van der Linden M, van Hees CL, van Beurden M, et al. The Paget Trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease［J］. Am J Obstet Gynecol, 2022,227（2）:250.e1⁃250.e8. doi: 10.1016/j.ajog.2022.04.012.

[1]	陈浩天刘莲张婷刘青锋李晓雪刁萍蒋献. 鲜红斑痣发病及进展机制研究进展[J]. 中华皮肤科杂志, 2024, 57(7): 661-664.
[2]	蒋献刘莲张婷. 鲜红斑痣的治疗现状及展望[J]. 中华皮肤科杂志, 2024, 57(7): 590-594.
[3]	封梦荻王文氢. 转录因子和受体调控痤疮发病机制的研究进展[J]. 中华皮肤科杂志, 2024, 57(6): 575-578.
[4]	《乳房外Paget病诊治专家共识（版）》编写委员会专家组. [开放获取] 乳房外Paget病诊治专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 400-408.
[5]	鞠强李嘉祺. [开放获取] 寻常痤疮再认识：从发病机制到治疗策略[J]. 中华皮肤科杂志, 2024, 57(4): 289-294.
[6]	严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024, 57(4): 374-378.
[7]	宗杨永怡马楚君苏忠兰. 银屑病生物制剂治疗后湿疹化发生机制及应对策略[J]. 中华皮肤科杂志, 2024, 0(3): 20220578-e20220578.
[8]	刘亭微孟潇琦顾多多潘婼芯张悦许阳. 玫瑰痤疮发病机制的研究进展[J]. 中华皮肤科杂志, 2024, 57(2): 186-190.
[9]	岳超王涛段梦莹戴叶芹彭建中沈忠宋秀祖. 臀部双侧V-Y推进岛状皮瓣修复肛周Paget病术后缺损的应用[J]. 中华皮肤科杂志, 2024, 57(1): 58-61.
[10]	宋志强陈奇权葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723.
[11]	梁云生黎展宏伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023, 56(6): 552-558.
[12]	蒋佳怡王大光. 系统性疾病致甲改变机制研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220078-e20220078.
[13]	陈启韬李煜乾邵光辉朱晶朱麒麟李中明杜旭峰范卫新. 头皮糜烂性脓疱性皮病研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210803-e20210803.
[14]	王丽王千秋张瑞丽. 隐性梅毒研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220283-e20220283.
[15]	李瑞李弘扬周佳张韡曾学思. 晕痣的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20230318-e20230318.

乳房外Paget病发病机制研究进展

Pathogenesis of extramammary Paget′s disease

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 49

相关文章 15

Metrics

本文评价

推荐阅读 10